Tang Capital Management adds Infinity Pharmaceuticals (INFI) to its portfolio

Infinity Pharmaceuticals (INFI) : Tang Capital Management added new position in Infinity Pharmaceuticals during the most recent quarter end. The investment management firm now holds 460,000 shares of Infinity Pharmaceuticals which is valued at $754,400 , the company said in a statement filed on Aug 15, 2016 with the SEC.Infinity Pharmaceuticals makes up approximately 0.39% of Tang Capital Management’s portfolio.

Other Hedge Funds, Including , Perceptive Advisors sold out all of its stake in INFI during the most recent quarter. The investment firm sold 100,000 shares of INFI which is valued $164,000. Dekabank Deutsche Girozentrale sold out all of its stake in INFI during the most recent quarter. The investment firm sold 21,500 shares of INFI which is valued $36,550.California Public Employees Retirement System reduced its stake in INFI by selling 3,100 shares or 3.06% in the most recent quarter. The Hedge Fund company now holds 98,300 shares of INFI which is valued at $172,025. Diam Ltd. added INFI to its portfolio by purchasing 30,911 company shares during the most recent quarter which is valued at $54,094.

Infinity Pharmaceuticals (INFI) witnessed a volatile trading activity on Thursday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $1.51 and reached the intraday high at $1.6. The bulls started the profit booking and pushed the shares to intraday low of $1.51. The trading session was marked by a volume range of 1,26,399 shares exchanging hands. The 52-week high of the shares is $10.85 and the 52-week low is $1.24. The market cap of the company stands at $75 M and there are 4,95,87,998 shares in public circulation.

On the company’s financial health, Infinity Pharmaceuticals reported $1.05 EPS for the quarter, beating the analyst consensus estimate by $ 1.86 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.81. The company had revenue of $9.47 million for the quarter, compared to analysts expectations of $10.19 million. The company’s revenue was up 94.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.78 EPS.

Many Wall Street Analysts have commented on Infinity Pharmaceuticals. Shares were Reiterated by Wedbush on Aug 10, 2016 to “Neutral” and Lowered the Price Target to $ 1 from a previous price target of $1.25 .Shares were Downgraded by RBC Capital Mkts on Jun 15, 2016 to ” Sector Perform” and Lowered the Price Target to $ 2 from a previous price target of $12 .Infinity Pharmaceuticals was Downgraded by Jefferies to ” Hold” on Jun 15, 2016.

Infinity Pharmaceuticals Inc. is a biopharmaceutical company that is engaged in the discovery development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib also known as IPI-145 an oral dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. In addition to duvelisib the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies) a worldwide investigation of duvelisib in blood cancers.

Leave a Reply

Infinity Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Infinity Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.